Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
3.670
+0.070 (1.94%)
Dec 24, 2025, 1:00 PM EST - Market closed
Fortress Biotech Revenue
Fortress Biotech had revenue of $17.63M in the quarter ending September 30, 2025, with 20.52% growth. This brings the company's revenue in the last twelve months to $57.79M, up 1.39% year-over-year. In the year 2024, Fortress Biotech had annual revenue of $57.68M, down -31.76%.
Revenue (ttm)
$57.79M
Revenue Growth
+1.39%
P/S Ratio
1.58
Revenue / Employee
$616,861
Employees
101
Market Cap
113.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
| Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
| Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
| Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
| Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
| Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
| Dec 31, 2018 | 26.88M | 9.64M | 55.88% |
| Dec 31, 2017 | 17.25M | 11.09M | 180.09% |
| Dec 31, 2016 | 6.16M | 5.29M | 613.44% |
| Dec 31, 2015 | 863.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FBIO News
- 10 days ago - Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewsWire
- 15 days ago - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewsWire
- 5 weeks ago - Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewsWire
- 7 weeks ago - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 2 months ago - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire